

## DESCRIPTION


<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human M-CSF in direct ELISAs and Western blots. In direct ELISAs and Western blots, this antibody shows less than 5% cross-reactivity with recombinant mouse M-CSF.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Protein A or G purified
<b>Immunogen</b>	<i>E. coli</i> -derived recombinant human M-CSF Glu33-Ser190 Accession # NP_757350
<b>Endotoxin Level</b>	<0.10 EU per 1 µg of the antibody by the LAL method.
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	Recommended Concentration	Sample
<b>Western Blot</b>	1 µg/mL	Recombinant Human M-CSF (Catalog # 216-MC)
<b>Neutralization</b>		Measured by its ability to neutralize M-CSF-induced proliferation in the M-NFS-60 mouse myelogenous leukemia lymphoblast cell line [Halenbeck, R. <i>et al.</i> (1989) <i>Biotechnology</i> 7:710]. The Neutralization Dose (ND <sub>50</sub> ) is typically 0.05-0.15 µg/mL in the presence of 2.5 ng/mL Recombinant Human M-CSF.

## DATA



## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 1 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
<b>Stability &amp; Storage</b>	<p><b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b></p> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

M-CSF, also known as CSF-1, is a four- $\alpha$ -helical-bundle cytokine that is the primary regulator of macrophage survival, proliferation and differentiation (1–3). M-CSF is also essential for the survival and proliferation of osteoclast progenitors (1, 4). M-CSF also primes and enhances macrophage killing of tumor cells and microorganisms, regulates the release of cytokines and other inflammatory modulators from macrophages, and stimulates pinocytosis (2, 3). M-CSF increases during pregnancy to support implantation and growth of the decidua and placenta (5). Sources of M-CSF include fibroblasts, activated macrophages, endometrial secretory epithelium, bone marrow stromal cells and activated endothelial cells (1–5). The M-CSF receptor (*c-fms*) transduces its pleotropic effects and mediates its endocytosis. M-CSF mRNAs of various sizes occur (3–9). Full length human M-CSF transcripts encode a 522 amino acid (aa) type I transmembrane (TM) protein with a 464 aa extracellular region, a 21 aa TM domain, and a 37 aa cytoplasmic tail that forms a 140 kDa covalent dimer. Differential processing produces two proteolytically cleaved, secreted dimers. One is an N- and O- glycosylated 86 kDa dimer, while the other is modified by both glycosylation and chondroitin-sulfate proteoglycan (PG) to generate a 200 kDa subunit. Although PG-modified M-CSF can circulate, it may be immobilized by attachment to type V collagen (8). Shorter transcripts encode M-CSF that lacks cleavage and PG sites and produces an N-glycosylated 68 kDa TM dimer and a slowly produced 44 kDa secreted dimer (7). Although forms may vary in activity and half-life, all contain the N-terminal 150 aa portion that is necessary and sufficient for interaction with the M-CSF receptor (10, 11). The first 223 aa of mature human M-CSF shares 88%, 86%, 81% and 74% aa identity with corresponding regions of dog, cow, mouse and rat M-CSF, respectively (12, 13). Human M-CSF is active in the mouse, but mouse M-CSF is reported to be species-specific.

## References:

1. Pixley, F.J. and E.R. Stanley (2004) Trends Cell Biol. **14**:628.
2. Chitu, V. and E.R. Stanley (2006) Curr. Opin. Immunol. **18**:39.
3. Fixe, P. and V. Praloran (1997) Eur. Cytokine Netw. **8**:125.
4. Ryan, G.R. *et al.* (2001) Blood **98**:74.
5. Makrigiannakis, A. *et al.* (2006) Trends Endocrinol. Metab. **17**:178.
6. Nandi, S. *et al.* (2006) Blood **107**:786.
7. Rettenmier, C.W. and M.F. Roussel (1988) Mol. Cell Biol. **8**:5026.
8. Suzu, S. *et al.* (1992) J. Biol. Chem. **267**:16812.
9. Manos, M.M. (1988) Mol. Cell. Biol. **8**:5035.
10. Koths, K. (1997) Mol. Reprod. Dev. **46**:31.
11. Jang, M-H. *et al.* (2006) J. Immunol. **177**:4055.
12. Kawasaki, E.S. *et al.* (1985) Science **230**: 291.
13. Wong, G.G. *et al.* (1987) Science **235**:1504.